Hino, Japan

Hitoshi Fujimori

This inventor holds 1 USPTO granted patent. Top assignee: Teijin Limited. Active years: 1979.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1979

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hitoshi Fujimori: Innovator in Pharmaceutical Chemistry

Introduction

Hitoshi Fujimori is a notable inventor based in Hino, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. His work has led to advancements in the treatment of various medical conditions.

Latest Patents

Fujimori holds a patent for benzodiazepine derivatives and pharmaceutical compositions containing novel 4H-pyrrolo[1,2-a][1,4]benzodiazepine derivatives. The patent describes compounds that are prepared by subjecting specific compounds to protective group-elimination and cyclization. These compounds exhibit useful properties such as anti-anxiety, sedative, anti-convulsant, muscle relaxant, and hypnotic effects, while also demonstrating low toxicity. He has 1 patent to his name.

Career Highlights

Hitoshi Fujimori is associated with Teijin Limited, a company known for its innovative approaches in various sectors, including pharmaceuticals. His work at Teijin has allowed him to focus on developing compounds that can significantly improve patient outcomes.

Collaborations

Fujimori has collaborated with notable colleagues, including Takeshi Hara and Yasutaka Kayama. These collaborations have contributed to the advancement of research and development in the pharmaceutical field.

Conclusion

Hitoshi Fujimori's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key inventor in the industry. His work continues to impact the development of effective therapeutic agents.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…